Intervention
Pemetrexed + Cisplatin /Carboplatin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319 · 2026-06-15
RECRUITINGASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyNCT07109531 · 2025-08-04
RECRUITINGA Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS MutationsNCT06835569 · 2025-03-05
RECRUITINGBefotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsNCT07709585 · 2026-07-05
NOT_YET_RECRUITINGHSK41959 With Standard Therapy in Solid Tumors With MTAP DeletionNCT07699757 · 2026-07-01
NOT_YET_RECRUITINGA Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNCT06110663 · 2023-12-30
UNKNOWNStudy on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationNCT05015608 · 2021-11-22
COMPLETEDCommon conditions
Non-Small Cell Lung Cancer3Advanced Solid Tumors2Advanced Non-small Cell Lung Cancer (NSCLC)1Cancer1CRC (Colorectal Cancer)1EGFR Exon 19 Deletion Mutation1EGFR Exon 21 L858R Mutation1EGFR Exon 21 Mutation1Locally Advanced or Metastatic NSCLC1Non Small Cell Lung Cancer (Squamous or Non Squamous)1NSCLC (Non-small Cell Lung Cancer)1Pancreatic Ductal Adenocarcinoma (mPDAC)1PDAC - Pancreatic Ductal Adenocarcinoma1Stage 4 NSCLC1
Leading sponsors
Trial status mix
RECRUITING3
NOT_YET_RECRUITING2
COMPLETED1
UNKNOWN1
Phase mix
PHASE34
PHASE12
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.